Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Swiss Exchange  >  Novartis AG    NOVN   CH0012005267

Delayed Quote. Delayed  - 09/27 10:26:19 am
78.25 CHF   +0.32%
09/26 NOVARTIS : announces positive top-line results from ASCEND-4, a Phas..
09/26 NOVARTIS : receives three new FDA approvals for the expanded use of ..
09/26 NOVARTIS : Nouscom Appoints New Chief Operating Officer and Strength..
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

UK's NICE Backs Novartis Eye Drug, Reversing Earlier Guidance

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/05/2012 | 01:16am CEST

By Marta Falconi

ZURICH--The U.K.'s health costs watchdog has reversed earlier guidance and now recommends eye drug Lucentis for a new use, after its maker Novartis AG (>> Novartis AG) offered a better price.

The U.K's National Institute for Health and Clinical Excellence, or NICE, recommends the drug for certain patients who suffer from visual impairment caused by diabetic macular oedema, the regulator said Friday. Without discount, Lucentis costs 742.17 pounds ($1,195) per injection and is given monthly, NICE said.

The new draft guidance is now up for consultation.

NICE decides if particular treatments should be used on the state-run National Health Service. The watchdog had previously rejected Lucentis for diabetic macular oedema, a condition caused by fluid collecting in the central part of the retina, which leads to blurred central vision and other problems.

The drug is already recommended to treat wet age-related macular degeneration.

Novartis said it was pleased with NICE's decision, but lamented the watchdog's move to restrict Lucentis to only those patients with more thickened retinas.

"This has undervalued the benefits that Lucentis provides to all patients with visual impairment due to diabetic macular oedema," the company said.

The Swiss company said it will continue to work with NICE and other health authorities until final draft guidance is issued by early 2013.

Lucentis, which generated nearly 2.05 billion Swiss francs ($2.19 billion) in sales in 2011, was co-developed by Novartis and Swiss rival Roche Holding AG (ROG.VX). Novartis markets the medicine outside the U.S.

Write to Marta Falconi at marta.falconi@dowjones.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Stocks mentioned in the article : Novartis AG
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on NOVARTIS AG
09/26 NOVARTIS : announces positive top-line results from ASCEND-4, a Phase III trial ..
09/26 NOVARTIS : receives three new FDA approvals for the expanded use of Ilaris treat..
09/26 NOVARTIS : Nouscom Appoints New Chief Operating Officer and Strengthens the Boar..
09/23 NOVARTIS : receives three new FDA approvals for the expanded use of Ilaris treat..
09/23 NOVARTIS : Alcon Research Assigned Patent
09/23 NOVARTIS : announces positive top-line results from ASCEND-4, a Phase III trial ..
09/22 DOES NOVARTIS AG (NYSE : NVS) Have The Solution For Malaria?
09/22 NOVARTIS : Pharma star celebrates two special anniversaries
09/21 NOVARTIS : Novel Novartis Compound Shows Potential as Effective Therapy for Trea..
09/21 NOVARTIS : Novel Novartis malaria compound shows potential to be effective again..
More news
Sector news : Pharmaceuticals - NEC
08:49aDJPFIZER : Scraps Plan to Break Up Company -- WSJ
09/26DJMYLAN : EpiPen Pretax Profits 60% Higher Than Number Told to Congress -- 3rd Upd..
09/26 MYLAN : faces scrutiny over EpiPen profit data shown to Congress
09/26DJPFIZER : Throws Out Plan to Split Into Two Companies -- 2nd Update
09/26DJPfizer Throws Out Plan to Split Into Two Companies
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
09/26 Array Plays Catch-Up In Braf-Mek Derby
09/26 BIOTECH FORUM DAILY DIGEST : Behind Some Big Moves In Small Caps. Spotlight On V..
09/26 Array Bio's encorafenib-binimetinib combo successful in late-stage melanoma s..
09/23 FDA OKs three new uses for Novartis' Ilaris
09/23 Fovista Results Could See Novartis Dig Deep, And Gilead's NASH Data
Advertisement
Financials ($)
Sales 2016 48 892 M
EBIT 2016 11 365 M
Net income 2016 7 821 M
Debt 2016 14 753 M
Yield 2016 3,53%
P/E ratio 2016 23,58
P/E ratio 2017 21,31
EV / Sales 2016 4,62x
EV / Sales 2017 4,48x
Capitalization 211 231 M
More Financials
Chart NOVARTIS AG
Duration : Period :
Novartis AG Technical Analysis Chart | NOVN | CH0012005267 | 4-Traders
Full-screen chart
Technical analysis trends NOVARTIS AG
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 30
Average target price 89,9 $
Spread / Average Target 12%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Joseph Jimenez Chief Executive Officer
Hans Jörg Reinhardt Independent Non-Executive Chairman
Harry Kirsch Chief Financial Officer
Vasant Narasimhan Chief Medical Officer & Head-Drug Development
Srikant Madhav Datar Independent Non-Executive Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
NOVARTIS AG-8.70%211 231
JOHNSON & JOHNSON14.66%322 232
ROCHE HOLDING LTD.-11.18%215 081
PFIZER INC.4.21%204 049
MERCK & CO., INC.17.66%171 858
GLAXOSMITHKLINE PLC20.39%103 357
More Results